Aggregator

Sweeping proposed rule, now open for comments, would also restrict foreign collaborations and remove federal funding for open-access fees

Feeling constantly drained might not just be about poor sleep or working too hard. Researchers in Japan found that low levels of key vitamins — especially vitamin B12 and folate — may quietly contribute to fatigue and lack of motivation, even in otherwise healthy people.

Cambridge researchers created miniature brain-and-spinal-cord systems in the lab that can send signals and even trigger tiny muscle contractions. They discovered that human neurons gradually lose their ability to regrow after damage during development — but that ability can potentially be switched back on. The team identified a gene network controlling this process and found that an existing hormone drug dramatically boosted nerve fiber regrowth.

CBD may be doing far more than just easing pain or anxiety — new research suggests it could help fight Alzheimer’s disease by calming the brain’s runaway immune response. In experiments using Alzheimer’s mice, scientists found that inhaled CBD reduced key drivers of neuroinflammation, a damaging process increasingly linked to memory loss and brain degeneration.

Researchers are developing a futuristic alternative to LASIK that reshapes the eye without lasers or incisions. Using mild electrical pulses and platinum contact lenses, they temporarily soften the cornea so it can be molded into a new shape. Early tests on rabbit eyes successfully corrected nearsightedness in about a minute while preserving the eye’s structure.

For more than a century, pianists and music teachers have argued over whether a performer’s touch can actually change the tone color of a piano note — and now scientists say the answer is yes. Using a cutting-edge sensor system that tracked piano key movements at 1,000 frames per second, researchers discovered that elite pianists subtly manipulate keys in ways that listeners can genuinely hear, even if they’ve never played piano before.

No abstract

No abstract

No abstract

No abstract

BACKGROUND: Alzheimer's disease neuropathology, characterised by amyloid β (Aβ) and phosphorylated-tau (p-tau) protein accumulation, has primarily been assessed with biomarkers in clinical samples of older adults. Less is known about plasma biomarkers of Alzheimer's disease neuropathology and their associations with cognitive outcomes in midlife in diverse community-based samples. Our goal was to address these gaps.

BACKGROUND: Tau PET imaging has emerged as a critical biomarker for Alzheimer's disease, informing diagnosis, staging, and therapeutic selection. We investigated whether PET tracer selection alters tau detection.

BACKGROUND: Prasinezumab has previously shown potential for reducing the progression of motor signs (Movement Disorder Society-sponsored Revision of the Unified Parkinson's Disease Rating Scale [MDS-UPDRS] Part III) in patients with early-stage Parkinson's disease who were treatment-naive or receiving monoamine oxidase type B (MAO-B) inhibitors. The aim of the PADOVA trial was to evaluate the efficacy and safety of prasinezumab in a broader population of patients receiving stable symptomatic...

Alzheimer's disease is the leading cause of dementia and among the top ten leading causes of death in high-income countries. Exponential advances in epidemiology, genetics, diagnostic imaging and fluid biomarkers, treatment, and prevention in the last decade reinforce the notion that we are entering a new era in the clinical management of Alzheimer's disease. However, far from triumphalism, this momentum should be accelerated to achieve the goals of preventing Alzheimer's disease and arresting...